title: [Endobronchial metastases from breast cancer: a clinicopathological and survival analysis].
abstract: OBJECTIVE
  Endobronchial metastases (EBM) secondary to extrapulmonary solid malignant tumors are rare but may occur. The most common extrathoracic malignancies associated with EBM are colorectal, renal and breast cancer. This study aimed to evaluate the clinicopathological aspects of EBM from breast cancer and the prognosis of the patients.
  
  
  METHODS
  Clinicopathological data of 11 cases diagnosed as EBM from breast cancer treated in our hospital from 2003 to 2010 were re-evaluated. Their symptoms, recurrence interval, radiological features, histopathological properties, and prognosis were assessed.
  
  
  RESULTS
  Eleven cases were diagnosed by bronchoscopic bronchial biopsy. The median interval from diagnosis of breast cancer was 57 months (range: 11 - 189 mo). All patients had other proven metastases when the EBM was diagnosed. The most frequently observed symptoms were cough (8 cases). Interestingly, two patients were asymptomatic. Hilar mass (5 cases) was a common radiological finding. No disaccordance between the hormone receptor status in the primary and metastatic lesions in these patients was found. The median survival after EBM diagnosis was 21 months (range: 6 - 36) with four patients still alive and one of these four patients was surviving more than 7 years.
  
  
  CONCLUSIONS
  On average, EBM is diagnosed about 5 years after the diagnosis of breast cancer, which is a relatively long lead time, but the median survival time is short, as 21 months in our group. The treatment plan must be individualized, because in some cases, long-term survival can be expected.
authors.affiliation: Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.forename: Bing-he
authors.initials: BH
authors.lastname: Xu
authors.forename: Jia-yu
authors.initials: JY
authors.lastname: Wang
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.forename: Pin
authors.initials: P
authors.lastname: Zhang
authors.forename: Peng
authors.initials: P
authors.lastname: Yuan
authors.forename: Fei
authors.initials: F
authors.lastname: Ma
authors.forename: Ying
authors.initials: Y
authors.lastname: Fan
authors.forename: Rui-gang
authors.initials: RG
authors.lastname: Cai
authors.forename: Qiao
authors.initials: Q
authors.lastname: Li
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000556:secondary*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077289:Letrozole; D008207:Lymphatic Metastasis; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole